01/25/23 7:45 AMNasdaq : INMB clinical triallow floatINmune Bio, Inc. Announces Pre-Clinical Data That Support a Pioneering Approach to Treating Duchenne Muscular DystrophyINmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, in collaboration with Professor Armando Villalta, Ph.D. ofRHEA-AIneutral
12/22/22 8:00 AMNasdaq : INMB low floatINmune Bio, Inc., Virginia Commonwealth University, and Barrow Neurological Institute Receive Department of Defense Funding to Study the Role of Traumatic Brain Injury in the Development of Alzheimer’s DiseaseINmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness theRHEA-AIneutral
12/08/22 8:00 AMNasdaq : INMB low floatINmune Bio, Inc. Data at ASH Highlight Innovative Natural Killer Cell Therapeutic Platform Showing 100+ Day Persistence of Cancer Killing Memory Like NK Cells in Patients with AML/MDS Following Treatment with INKmune™INmune Bio, Inc. (NASDAQ: INMB) (“INMB” or “the Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease will present data from UK patients with MDS orRHEA-AIneutral
12/06/22 4:00 PMNasdaq : INMB low floatINmune Bio, Inc. Reports Combination Therapy with INB03™ Overcomes Resistance to Trastuzumab-Deruxtecan in MUC4 expressing HER2+ Breast CancerNeutralizing soluble TNF with INB03™ overcomes resistance to trastuzumab-deruxtecan in MUC4 expressing HER2+breast cancer. Combination therapy of INB03™ and trastuzumab-deruxtecan presented at the 45th annual San Antonio Breast Cancer Symposium today Boca Raton, Florida, Dec. 06, 2022 (GLOBERHEA-AIpositive
11/29/22 8:00 AMNasdaq : INMB clinical triallow floatINmune Bio, Inc. Focused on Novel Clinical Trial Designs to Advance Next Generation of Alzheimer’s Disease TreatmentsINmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunologyRHEA-AIneutral
11/14/22 9:00 AMNasdaq : INMB clinical triallow floatINmune Bio, Inc. Receives Health Canada “No Objection Letter” to Commence Clinical Trial of XPro1595 in Mild Alzheimer’s DiseaseINmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces that Health Canada has issued the Company aRHEA-AIneutral
11/02/22 4:00 PMNasdaq : INMB low floatINmune Bio, Inc. Announces Third Quarter 2022 Results and Provides Business UpdateINmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fightRHEA-AIneutral
10/26/22 8:10 AMNasdaq : INMB conferencesearningslow floatINmune Bio, Inc. to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on Wednesday, November 2INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system toRHEA-AIneutral
10/19/22 8:00 AMNasdaq : INMB low floatINmune Bio, Inc. Announces Positive Solid Tumor Efficacy Data in Multiple Cancer Cell Lines for INKmuneINmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments thatRHEA-AIneutral
09/07/22 9:00 AMNasdaq : INMB conferenceslow floatINmune Bio, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference and the Baird Global Healthcare ConferenceINmune Bio (NASDAQ: INMB), a clinical- stage immunology company focused on developing treatments that harness the patient’s immune system to fight disease, announced today that RJ Tesi, M.D., Chief Executive Officer will present a corporateRHEA-AIneutral